In a T2D monotherapy study,

INVOKANA® helped lower A1C in patients with T2D
in need of glycemic control1

INVOKANA® helped lower A1C in patients with T2D in need of glycemic control1

Adjusted mean change from baseline in a monotherapy study1

Chart showing A 1 C level of patients taking INVOKANA 100 mg vs INVOKANA 300 mg vs Placebo over 26 weeks.

In patients with an eGFR ≥60 mL/min/1.73 m2 needing additional glycemic control, the dose can be increased to 300 mg once daily.2

T2D=type 2 diabetes.

Monotherapy vs placebo + diet and exercise at 26 weeks

The efficacy and safety of INVOKANA® monotherapy were assessed in subjects with type 2 diabetes mellitus who were inadequately controlled with diet and exercise. In this 26-week, double-blind, placebo-controlled study, 584 patients were randomized to receive placebo (n=192), INVOKANA® 100 mg (n=195), or INVOKANA® 300 mg (n=197). Mean baseline A1C values were, respectively, 7.97%, 8.06%, and 8.01%. The primary endpoint was the change in A1C from baseline to week 26. Prespecified secondary endpoints included change in fasting plasma glucose, change in percent body weight, and change in systolic blood pressure.1,2

References: 1. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372-382. 2. INVOKANA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.